Stevanato Group (NYSE:STVN) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Stevanato Group S.p.A. (NYSE:STVN) saw an uptick in trading volume on Wednesday. 625,050 shares were traded during mid-day trading, an increase of 21% from the average daily volume of 516,235 shares. The stock last traded at €13.69 and had previously closed at €14.10.

More Stevanato Group News

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Third-quarter revenue rose 8% to €326.1 million, and Zacks reported that quarterly earnings and revenue exceeded consensus estimates. A separate valuation analysis argued STVN could be about 42% undervalued, offering a more positive view of the stock’s potential. Stevanato Group Q3 results Zacks Q3 estimates Undervaluation analysis
• Negative Sentiment: Management expects only low-single-digit growth in 2027, with lower GLP-1 syringe volumes linked to one customer. The outlook may be overshadowing the quarter’s revenue growth and raising concerns about customer concentration and near-term growth. 2027 outlook and GLP-1 demand
• Negative Sentiment: Law firms announced investigations into whether Stevanato’s disclosures met securities-law requirements, following the share-price decline and concerns about GLP-1-related disclosures. These are investigations, not findings of wrongdoing, but could add uncertainty for investors. Kehoe Law investigation notice Legal investigation coverage

Analyst Ratings Changes

Several research firms have recently weighed in on STVN. UBS Group assumed coverage on Stevanato Group in a research report on Wednesday, September 9th. They set a “neutral” rating and a $23.00 target price on the stock. Weiss Ratings upgraded shares of Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. Deutsche Bank Aktiengesellschaft began coverage on shares of Stevanato Group in a research note on Wednesday, October 7th. They issued a “hold” rating on the stock. Finally, William Blair lowered Stevanato Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy”.

Stevanato Group Stock Performance

The firm has a fifty day moving average of €20.35 and a 200 day moving average of €18.11. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.61 and a quick ratio of 1.08. The stock has a market capitalization of $3.81 billion, a price-to-earnings ratio of 22.70, a price-to-earnings-growth ratio of 1.62 and a beta of 0.80.

Stevanato Group (NYSE:STVN) last released its quarterly earnings data on Tuesday, November 3rd. The company reported €0.16 EPS for the quarter, missing the consensus estimate of €0.17 by (€0.01). The company had revenue of €326.06 million during the quarter. Stevanato Group had a return on equity of 10.43% and a net margin of 10.99%. On average, sell-side analysts anticipate that Stevanato Group S.p.A. will post 0.69 earnings per share for the current fiscal year.

Insider Transactions at Stevanato Group

In related news, Director Luciano Santel sold 2,023 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of €20.09, for a total transaction of €40,642.07. Following the completion of the sale, the director owned 4,739 shares of the company’s stock, valued at approximately €95,206.51. This represents a 29.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Elisabetta Magistretti sold 2,045 shares of Stevanato Group stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of €20.09, for a total value of €41,084.05. Following the transaction, the director owned 2,930 shares in the company, valued at approximately €58,863.70. The trade was a 41.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 21,926 shares of company stock worth $459,738.

Hedge Funds Weigh In On Stevanato Group

Several institutional investors have recently modified their holdings of the business. Squarepoint Ops LLC increased its stake in shares of Stevanato Group by 131.2% during the second quarter. Squarepoint Ops LLC now owns 193,311 shares of the company’s stock worth $3,493,000 after buying an additional 109,702 shares during the period. Wellington Management Group LLP purchased a new position in Stevanato Group in the second quarter valued at $22,621,000. Confluence Investment Management LLC acquired a new stake in Stevanato Group in the second quarter valued at $6,062,000. Fenimore Asset Management Inc acquired a new stake in Stevanato Group during the third quarter worth approximately $12,212,000. Finally, Royal Bank of Canada lifted its position in shares of Stevanato Group by 15.8% during the 1st quarter. Royal Bank of Canada now owns 421,696 shares of the company’s stock worth $5,798,000 after buying an additional 57,536 shares during the last quarter.

Stevanato Group Company Profile

Stevanato Group S.p.A. is an Italy-based provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and healthcare industries. Founded in 1949, the company has developed from a glass-packaging manufacturer into an integrated supplier serving customers throughout the global pharmaceutical supply chain.

The company manufactures primary packaging products, including glass vials, syringes, cartridges and ampoules, as well as components and systems used to contain and administer injectable medicines.